|
Market Closed -
Nasdaq
16:00:00 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 45.49 USD | -1.32% |
|
-3.62% | +62.58% |
| 09-04 | After obesity, pharma seeks its next mega-blockbuster in sleep |  |
| 08-25 | Alkermes plc Publishes Data From Vibrance-1 Phase 2 Study Of Alixorexton In Adults With Narcolepsy Type 1 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 7.63B | - | ||||
| 48.01B | |||||
| 44.44B | - | - | - | - | - |
| 42.67B | |||||
| 39.96B | |||||
| 32.75B |
- Stock Market
- Stocks
- ALKS Stock
- Charts Alkermes plc
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
